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http://dx.doi.org/10.1016/j.bgm.201Abstract Src, a membrane-associated nonreceptor tyrosine kinase, belongs to the Src family
kinase group (SFK). Dysregulation and excessive activity of Src has been reported in multiple
human cancers. Src plays a critical role in many aspects of tumor development including the
proliferation, survival, adhesion, invasion, and migration in multiple tumor types. Additionally,
Src also plays a role in regulating the microenvironment of the cancers, and promotes the
angiogenic signaling pathway for angiogenesis. However, the expression of Src in human tran-
sitional cell carcinoma is still unclear. In the current study, we demonstrated the expression
level of c-Src in the human transitional cell carcinoma tissue array and compared it with
normal urothelial tissues. Surprisingly, c-Src is greatly expressed in the normal urothelial tis-
sues. However, decreasing expression of c-Src is observed in a grade-dependent manner. This
finding is also confirmed in human bladder cancer cell lines. This observation shed light on a
new opportunity to elucidate the pathways and biologic functions of c-Src involved in tumor-
igenesis, progression and prognosis of human transitional cell carcinoma. Moreover, Src inhib-
itors should be used with caution in cancer therapeutics to treat human transitional cell
carcinoma.
Copyright ª 2014, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.of Medical Research, Chiayi Christian Hospital, Number 539, Jhongsiao Road, Chiayi City, Taiwan.
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Urothelial cancer (UC), including renal, pelvis, ureter, and
bladder cancers, is the second most common malignancy of
the genitourinary tract in the world and remains a signifi-
cant public health problem.1 There are more than 386,000
new cases of bladder cancer diagnosed in the world, and it
has been estimated that 150,200 deaths occurred in 2008
because of the disease.1 In the United States in 2011, more
than 69,000 new cases were expected and approximately
14,990 deaths resulting from bladder cancer were pro-
jected for 2011.2 Additionally, UC is the seventh leading
cause of male malignant neoplasm in Taiwan.3 In Taiwan,
the incidence and mortality rates (per 100,000) of UC are
about 8.93 and 3.00 for men and 3.87 and 1.36 for women,
respectively. The incidence rate is particularly high on the
southwestern coast of Taiwan, suggesting that UC in these
areas may have unique carcinogenesis pathways.3 Transi-
tional cell carcinoma (TCC) accounts for more than 90% of
UCs, among which 75% are not muscle invasive and 20e30%
are muscle invasive.4 Despite good prognosis for patients
whose UCs are not muscle invasive, recurrence is common
and up to 30% of recurrence progression is seen in patients
with muscle-invasive UCs.4 Approximately 50% of patients
with muscle-invasive cancer, including those who progress
to this state, already harbored occult distant metastases
and a poor 5-year survival rate.5
The etiology of bladder cancer is heterogeneous and can
be classified into three subsets: genetic and molecular ab-
normalities, chemical or environmental exposures, and
chronic irritation. Many risk factors, including cigarette
smoking, carcinogenic chemical exposure, chronic in-
fections, pelvic irradiation, arsenic in drinking water, ge-
netic polymorphisms, and genetic and epigenetic
alterations, are involved in the tumorigenesis, progression,
and metastasis of bladder cancer.3,6,7 Additionally, the
grade and stage of bladder cancer has been proved to
contribute to patient survival rates.8 Moreover, research
shows that multiple tumor-associated proteins are related
to the degree of malignancy in bladder cancer; accordingly,
defining the role of various proteins involved in tumori-
genesis and tumor progression is important.
Recently, the roles of Src in tumor progression and
metastasis have been well documented in multiple human
cancers.9 Src, a membrane-associated nonreceptor tyrosine
kinase, belongs to the Src family kinase group (SFK), which
involves a number of important signal transduction path-
ways and has various effects on cellular function, including
cell survival, proliferation, differentiation, and angiogen-
esis.10 Src typically is expressed ubiquitously and is pre-
dominantly expressed in platelets, neuronal tissue, and
bone.11 Src activation by several mechanisms, including
phosphorylation of tyrosine residues, particularly in the
regulatory domain, has been documented.12 Src has been
identified to be a proto-oncogene, and over the past 30
years multiple studies demonstrated the overexpression or
increased activity of Src in a variety of neoplastic tissues.13
Src dysregulation not only can result in malignant trans-
formation and increasing metastases propensity but also
can contribute to chemotherapeutic resistance.14e16 Addi-
tionally, an interesting role of the Src pathway in regulatingtumor initiated cells and host immune response has been
reported. Src is activated under hypoxic conditions that
activate autophagy and enable tumor cells to escape
cytotoxic T cell-mediated killing.17 All together, the data
show that Src is one of the important proto-oncogenes that
contributes to tumorigenesis, tumor recurrence, metasta-
ses, and drug resistance. However, the expression of Src in
human transitional cell carcinoma is still unclear. In the
current study, we evaluate the expression of Src in the
human bladder tissues array and examine the levels of Src
in tumor progression.
Materials and methods
Cell lines and tissue microarray
Human transitional carcinoma cell lines, including 5637,
TSGH8301, BFTC905, HT1376, HT1197, and TCCSUP are pur-
chased from American Type Culture Collection (ATCC; Man-
assas, VA, USA) and were cultured in Dulbecco’s modified
Eagle’s medium (Gibco BRL, Grand Island, NY, USA) supple-
mented with 10% fetal bovine serum, penicillin (200 U/mL)
and streptomycin (100 mg/mL) at 37C in 5% CO2.
A bladder cancer tissue microarray slide (BL1002) was
purchased from U.S. Biomax Inc. (Rockville, MD, USA),
which contained 40 cases of human bladder carcinoma and
10 cases of normal tissues with duplicate cores. The path-
ologic diagnosis of each sample was determined from the
manufacturer’s data sheet (http://www.biomax.us/tissue-
arrays/Bladder/BL1002). The urothelial cells in the sam-
ples of J3 and J10 belonging to the control group were
missing. Moreover, one case (sample of F1, belonging to
Grade II group) of the microarray slide was lacking. In
addition, only 74 cases have the pathologic diagnosis of the
grade in this microarray. Moreover, no clinical outcome of
the samples was found in the manufacturer’s data sheet.
Because the tissue microarray was purchased from U.S.
Biomax Inc., Institutional Review Board approval was not
required.
Immunohistochemistry
The immunohistochemistry was performed as previously
described.18 The tissue microarray slide was stained with
anti-c-Src antibody (ab47405; Abcam, Cambridge, MA, USA)
for determination of absolute c-Src concentration and
further counterstained with hematoxylin. All of the steps of
immunohistochemistry were performed in accordance with
the manufacturer’s instructions, using a LSAB kit (Dako,
Glostrup, Denmark). The regions of normal urothelial cells
(NUCs) and TCCs in the normal slides and patient tissue
slides are demonstrated in Fig. S1 in the supplementary data
online. Sections of the control specimens and/or TCC
specimens were considered c-Src-positive (3þ; Fig. S1A and
S1B in the supplementary material online); strong staining
was detected in at least 10% of the NUCs or TCC cells;
equivocal (2þ; Fig. S1C in the supplementary material on-
line) and moderate/weak staining was detected in at least
10% of the cells; 1þ (negative; Fig. S1D in the supplementary
material online), whereas the staining was weak or detected
Table 1 Distribution of characteristics for transitional cell
carcinoma cases and normal controls.a
Characteristics TCC patients
(n Z 79)
Controls
(n Z 18)
Age (y) 61.8  12.3 30.9  12.0
Sex
Male 65 8
Female 14 10
Pathological grade
Grade 1 10
Grade 2 27
Grade 3 36
Clinical stage
Stage I 22
Stage II 39
Stage IIIeIV 18
TCC Z transitional carcinoma cells.
a The urothelial cells were missing in two cases (J3 and J10) of
the tissues in the control group, and one case (F1) of the tissue
was missing in the Grade II group. In addition, six cases in the
TCC group missed the pathologic diagnosis of the grade
(microarray panel display as the data sheet: http://www.
biomax.us/tissue-arrays/Bladder/BL1002).
Decreased Expression of c-Src 39in only one part of the membrane in at least 10% of the cells,
and 0 (also negative) in cases in which there was no staining
or staining of less than 10% of the tumor cells.
Western blotting
Human TCC cells were lysed in mammalian protein
extraction reagent lysis buffer (Thermo Scientific, Rock-
ford, IL, USA) containing a protease inhibitor cocktail
(Roche Diagnostics, Mannheim, Germany). The total lysate
was separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis and immunoblotted with the antibodies
of c-Src (Abcam) and glyceraldehyde 3-phosphate dehy-
drogenase (GADPH; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA). A secondary antibody (Santa Cruz
Biotechnology, Inc.) was added to measure the expression
levels of c-Src and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). GAPDH was used as the internal control.
Statistical analysis
Descriptive mean statistical analysis was performed to
summarize the status of patient data and c-Src. The fre-
quencydistribution of the sociodemographic characteristics,
including age, sex, and clinical characteristics (grade and
stage) was examined for all patients. The univariate analysis
was performed using the two-sided Fisher exact test to
determine the expression levels of c-Src and clinical char-
acteristics.19 IBM SPSS Statistics 21was used and p< 0.05was
considered to be statistically significant.
Results
Comparison of characteristics among TCC cases and
control groups
A total of 40 patients with TCC and 10 normal cases were
examined in duplicate in this study, and their characteris-
tics are summarized in Table 1. Age and sex were consid-
ered to be the significant differences among the control
group and patients with TCC because of the limitations of
the tissue microarray. Importantly, no significant differ-
ences were found in the distribution of age or sex between
Grades 1e3 and/or Stage IeIV with TCC groups.
The expression level of c-Src in the urothelial cells
in normal and TCC tissues
The expression of c-Src has been demonstrated to be
elevated in multiple cancers, including breast and prostate
cancers.11 However, the expression of c-Src was unclear in
the patients with TCC. To examine the expression of ab-
solute c-Src in the patients with TCC in vivo, human TCC (80
samples in 40 cases), and normal (20 samples in 10 cases)
tissue microarray (purchased from US Biomax Inc.) was
used. The expression of absolute c-Src was determined by
immunohistochemistry and was organized by grade (Fig. 1A)
or stage (Fig. 1B). We found that c-Src was highly expressed
in the urothelial and muscle cells in normal specimens. In
clinical studies, the TCC was derived from urothelial cells.Therefore, we compared the expression levels of c-Src in
the tissues among the control group (urothelial cells only
were evaluated) and patients with TCC. The expression of
c-Src was reduced significantly (p < 0.0001) in patients with
TCC (Fig. 1). Moreover, we also evaluated the expression of
c-Src in the control group and the groups of pathological
grades and stages. We found a significantly decreasing
tendency of c-Src in the pathological grades of patients
with TCC compared with the control group (normal vs.
Grade 1: p < 0.01; normal vs. Grade 2: p < 0.0001; normal
vs. Grade 3: p < 0.0001; Grade 1 vs. Grade 2: p < 0.05;
Grade 1 vs. Grade 2: p Z 0.106; Grade 2 vs. Grade 3:
pZ 0.199; Fig. 1C). In addition, this finding was also noted
in the control group and the groups classified by patholog-
ical stages (normal vs. Stage I: p < 0.0001; normal vs. Stage
II: p < 0.0001; normal vs. Stage III/IV: p < 0.0001; Stage I
vs. Stage II: p Z 0.408; Stage I vs. Stage III/IV: p Z 0.399;
Stage II vs. Stage III/IV: p Z 0.059; Fig. 1D). These data
suggest that c-Src expression was decreased in patients
with TCC. Moreover, patients with low pathologic diagnoses
exhibited higher levels of c-Src than those with high-grade
TCCs (Fig. 1C). Therefore, the expression level and roles of
c-Src in tumor recurrence, survival rate, and/or therapeu-
tic effects is worthy of further investigation.The expression level of c-Src in the human bladder
cancer cell lines
To confirm the expressions of c-Src in human transitional cell
carcinoma cells, the expression of c-Src in six human bladder
cancer cell lines was determined. Human bladder cell lines in
the current study were divided into three groups by tumor
grade with the original surgical specimen under the descrip-
tion of the ATCC illustration. The expression levels of c-Src
and GAPDH was detected by Western blot analysis in which
Figure 1 c-Src expression in the human bladder tissue-microarray. The tissue-microarray was used to determine the expression
of c-Src by immunohistochemistry, and the photographs were organized by the pathologic diagnosis with (A) grades and (B) stages.
The expression level of c-Src was quantified with score 0w3 by a pathologist, and the scores of the specimens were also organized
depending on the pathologic diagnosis with (C) grades and (D) stages.
Figure 2 c-Src expression in multiple human bladder cancer
cell lines. The total protein collected from various human
bladder cancer cell lines were analyzed with Western blotting
using anti-c-Src antibody. GAPDH was used as an internal
control. Two independent experiments were confirmed and
one of them is shown.
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pressions of c-Src in Grade 2 (5637 and TSGH8301), Grade 3
(BFTC905 and HT1376), and Grade 4 (HT1197 and TCCSUP)
cells were 0.86, 0.385, and 0.625, respectively (Fig. 2). We
found a high level of c-Src in low grade (Grade 2) cells of
human bladder cancer cells (Fig. 2). However, c-Src had low
expression in human bladder cancer cells (BFTC905, HT1376,
HT1197, and TCCSUP) with high-grade cells (Grades 3 and 4;
Fig. 2). These in vitro data proved that c-Srcwas decreased in
thehigh-gradeTCCcells,whichwere similar to thedata found
in vivo. Therefore, combining the in vivo and in vitro data in
current study,we suggested that expression of c-Src in human
TCC was reduced comparing with normal urothelial cells.
Discussion
We demonstrated that the expression of c-Src was reduced
in the tissues of patients with TCC in comparison with the
urothelial cells in normal bladder tissues (Fig. 1). Moreover,
in patients with TCC, the expression of c-Src was elevated
in the low grade (Grade 1) tissues and not in the high grade
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factors related to a significant difference between the
control group and patients with TCC (Table 1), and were
also found to be significant between the groups of grades
and stages of patients with TCC. Therefore, we speculated
that the characteristics of sex and age had no influence on
c-Src expression in the control group as well as various
grades and stages of patients with TCC. In addition, the
in vitro analysis confirmed the expression of c-Src in the
patients with TCC had a tendency to decrease between
low-grade and high-grade TCC cells (Fig. 2). In a previous
report, Fanning et al20 demonstrated that the activity of c-
Src was elevated in low-grade human bladder cancers and
not in the high-grade cases. Our findings were similar to the
observation of Fanning et al.20 However, Fanning et al20
could not identify the expression of c-Src in the human
normal mucosa by Western blotting. Here, we have
demonstrated that c-Src was overexpressed in the urothe-
lial cells in the normal specimens through immunohisto-
chemical staining (Fig. 1). Importantly, c-Src is also highly
expressed in the muscle cells in normal tissues (Fig. 1).
Therefore, our investigation is more specific and more sig-
nificant (urothelial cells was only evaluated) than the pre-
vious report. In addition, c-Src highly expressed in the
normal urothelial cells of human bladder tissue is a novel
observation in our report. Furthermore, membrane c-Src
was found more frequently in normal urothelial cells
compared with TCC cells. Despite this, cytoplasmic c-Src in
the TCC cells was usually observed in the TCC cells (Fig. S1
in the supplementary material online). This observation is
consistent with a previous report,21 and the biological
functions of c-Src in different regions of TCC cells require
further investigation.
The role of Src in tumor progression and metastasis had
been well documented in multiple human cancers.9 How-
ever, inhibition of Src by inhibitors could suppress the inva-
dopodia formation and prevent tumor cell migration.22 In
addition to actin-based invadopodia, microtubule-based
microtentacle (McTN) protrusion was also involved in capil-
lary retention of circulating tumor cells to distant organ
sites.23 Interestingly, inhibition of Src by SU6656 reportedly
inhibits invadopodia formation while promoting the forma-
tion of McTN.23,24 This finding suggests the dual role of Src in
regulating of the cytoskeleton of tumor cells. Src activation
for the primary tumor site could promote tumor cell invasion
and migration, whereas invadopodia formation dominated.
However, after the tumor cells were disseminated, inhibi-
tion of Src could promote higher McTN formation and
enhance McTN-mediated capillary retention of circulating
tumor cells to distant organ sites.24 Therefore, whether the
decreasing expression of c-Src in the higher grade of TCC
specimens signifying the dissemination already occurred
needs further investigation. Although previous reports25,26
have demonstrated the in vitro and in vivo antitumor ef-
fects of c-Src inhibitors, the targeting therapy of c-Src (such
as dasatinib, genistein, PP2, and AZD0530) in patients with
TCC also needs to be carefully considered.Conflicts of interest
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